XTALPI (02228) shares climbed more than 5% in morning trading. As of press time, the stock was up 4.66% at HK$8.205, with a turnover of HK$108 million.

The company recently announced that its innovative drug pipeline targeting hair loss treatment has officially entered the IND-enabling research stage. Systematic studies focused on key elements including the efficacy, safety, druggability, and CMC of candidate molecules have been launched, laying the foundation for an Investigational New Drug application.

It is reported that in the field of hair loss prevention, XTALPI has already achieved阶段性 results on the consumer health side. The company's self-developed "Gemini" molecules XTP-118 and XTP-016 have already been commercialized.

Notably, recently, multiple self-developed and empowered pipelines of XTALPI have successively reached key milestones including IND approvals and clinical trial initiations. The concentrated landing of pipeline achievements indicates that the AI and robotics-driven R&D system is moving from single-project validation to multi-project reuse, with the capability to drive scalable transformation of innovative assets gradually emerging.